Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Modafinil Fails to Reduce Cancer-Related Fatigue

May 13, 2014
By Dave Levitan
Article

Modafinil, which is commonly prescribed to manage fatigue in cancer patients, had no effect on fatigue in a new study of patients with non-small-cell lung cancer.

Modafinil molecule

Modafinil molecule

Modafinil, which is commonly prescribed to manage fatigue in cancer patients, had no effect on fatigue in a new study of patients with non-small-cell lung cancer (NSCLC).

“Fatigue is the most prevalent symptom experienced by patients with cancer, occurring in more than 60% of patients and more than 80% of those receiving cancer treatment,” wrote study authors led by Anna Spathis, MSc, of Addenbrookes Hospital in Cambridge, United Kingdom. The central nervous system stimulant modafinil has recently come into vogue as a fatigue treatment in spite of limited randomized evidence for any benefit. In the only randomized trial of patients receiving chemotherapy, “modafinil had a small impact only in a subgroup of patients with severe baseline fatigue.”

In the new trial, 208 NSCLC patients who were not treated with chemotherapy or radiotherapy in the preceding 4 weeks were randomized to either modafinil or matched placebo. Of the total cohort, 160 patients (75 modafinil patients, 85 placebo patients) completed both the baseline and day 28 questionnaires on fatigue and other outcomes.

Fatigue scores improved significantly from baseline to day 28 in both groups. For modafinil patients, the mean score change was 5.29; for placebo patients, the mean score change was 5.09 (P = 0.92). There was still no significant difference between the groups after adjustment for disease stage or age.

Secondary outcomes were also similar between the groups. Both groups saw an improvement in the Epworth Sleepiness Scale, though there was no difference between them (P = .94). There were also no differences between the modafinil and placebo groups with regard to a depression score (P = .39) and a quality of life score (P = .60). Patients were also asked to rate how helpful the study treatment was; 47% of modafinil patients and 23% of placebo patients said it was not helpful (P = .13).

The notably large placebo effect seen in this trial could be due to several factors, the authors noted, including an artifact related to participating in a clinical trial or simply the natural history of fatigue over time in these patients. The latter possibility is unlikely, however, given previous work showing that NSCLC patients tend to experience worsening fatigue over time.

“We argue that the clinically significant benefit seen in both arms of this trial is likely related to the placebo effect,” they conclude. Also notable in the study was a higher withdrawal rate in the modafinil arm: there were more withdrawals due to death, disease progression, and adverse events in the modafinil group than in the placebo group.

Currently, National Comprehensive Cancer Network guidelines recommend consideration of modafinil for cancer patients undergoing treatment. But the authors write that “there is insufficient evidence to prescribe modafinil for patients with cancer-related fatigue outside of a clinical trial context.”

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
Related Content
Advertisement

An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.

VT3989 Receives Orphan Drug Designation for the Treatment of Mesothelioma

Roman Fabbricatore
August 1st 2025
Article

An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


A proactive regimen reduces dermatologic AEs in patients with NSCLC who were treated with amivantamab and lazertinib, enhancing treatment adherence.

COCOON Regimen Shows Promise in Mitigating Dermatologic AEs During NSCLC Treatment

ONCOLOGY Staff
July 27th 2025
Article

A proactive regimen reduces dermatologic AEs in patients with NSCLC who were treated with amivantamab and lazertinib, enhancing treatment adherence.


Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.


A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved a 1-year event-free survival.

OST-HER2 Shows Significant EFS Improvement in Metastatic Lung Osteosarcoma

Roman Fabbricatore
July 1st 2025
Article

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved 1-year event-free survival.


AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

The Role of Artificial Intelligence in Enhancing Precision Medicine for NSCLC

Puneet Modgil, MD
June 24th 2025
Article

AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

Related Content
Advertisement

An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.

VT3989 Receives Orphan Drug Designation for the Treatment of Mesothelioma

Roman Fabbricatore
August 1st 2025
Article

An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


A proactive regimen reduces dermatologic AEs in patients with NSCLC who were treated with amivantamab and lazertinib, enhancing treatment adherence.

COCOON Regimen Shows Promise in Mitigating Dermatologic AEs During NSCLC Treatment

ONCOLOGY Staff
July 27th 2025
Article

A proactive regimen reduces dermatologic AEs in patients with NSCLC who were treated with amivantamab and lazertinib, enhancing treatment adherence.


Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.


A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved a 1-year event-free survival.

OST-HER2 Shows Significant EFS Improvement in Metastatic Lung Osteosarcoma

Roman Fabbricatore
July 1st 2025
Article

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved 1-year event-free survival.


AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

The Role of Artificial Intelligence in Enhancing Precision Medicine for NSCLC

Puneet Modgil, MD
June 24th 2025
Article

AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.